1998年首个核苷类似物药物拉米夫定推出之前，慢性乙肝病毒感染者可选的有效治疗途径一直都非常有限。
Effective treatment options for individuals with chronic hepatitis B infection were limited until 1998 when lamivudine, the first nucleoside analogue drug, was introduced.
为了解决个人和公众的健康问题，急需进行试验以便寻找既能有效治疗乙肝又不会诱导各种adap -VEM出现的现有药物的最佳组合。
To address individual and public health concerns, trials are urgently needed to find the optimal combination of existing drugs that are effective but do not induce the emergence of ADAP-VEMs.
目前，全世界多数国家用于治疗乙肝的药物为抗干扰素，但是其低的有效率(30- 40%)和昂贵的治疗费用及副作用限制了其应用。
Presently, the drug of treating HBV is interferon in most countries, but low efficiency (30-40%), high treatment expenditure and side effect limit its application.
这两种是针对乙肝病毒的药物，另外针对丙肝病毒也有一些新的治疗数据的报道。
These are the drugs for HBV, but also there are some data presented for Hepatitis C virus.
本发明还涉及治疗慢性乙肝药物的制备方法。
The invention also relates to a preparation method of the medicine for treating chronic hepatitis B.
结论：乙肝3号冲剂是治疗慢性乙型肝炎的较好药物。
Conclusion: HB Granule 3 is a better medicine to treat Chronic hepatitis b.
我的医生给我用的PEG-干扰素目前还没有被通过作为治疗乙肝的药物。
I am currently taking PEG Interferon for Hep B but it's just something that my Doctor is doing and it is not officially approved for Hep B.
我的医生给我用的PEG-干扰素目前还没有被通过作为治疗乙肝的药物。
I am currently taking PEG Interferon for Hep B but it's just something that my Doctor is doing and it is not officially approved for Hep B.
应用推荐